Zobrazeno 1 - 2
of 2
pro vyhledávání: '"Michèle Vintraud"'
Autor:
Marion Vandromme, Jean Philippe Spano, Olivier Cussenot, Chloé Rideau, Carole Corsini, Isabelle Treilleux, Michèle Vintraud, Ignace Vergote, Yves-Jean Bignon, Kevin S. Hughes, Bernard Baertschi, Eitan Friedman, Daniel Zarca, Marie Duboys de Labarre, Pascal Pujol, Jean Marc Rey, Joseph Gligorov, Ettore D. Capoluongo, Clarisse Duriez, Marion Imbert-Bouteille, Yann Neuzillet, Jean-Louis Mandel, Isabelle Ray-Coquard, Laurence Gladieff, Jose E. Alés Martínez, Frédérique Penault-Llorca, Karim Fizazi, Pierre Jean Lamy, Julie A. Vendrell, Pascal Hammel, Thibault De La Motte Rouge, Jesus Garcia Foncillas, Diether Lambrechts, Tatiana Kogut-Kubiak, Karen Baudry, William Jacot, William D. Foulkes, Frédéric Thomas, Sophie Nambot, Massimo Barberis, Michèle Anahory, Matti Aapro, Xavier Rebillard, Josep M. Piulats, Florence Duchamp, Steven A. Narod, Sylviane Olschwang, Banu Arun, Marc Bollet, Philp Beer, Clare Turnbull, Helen Hanson, Nicola Normanno, Virginie Galibert
Publikováno v:
Dipòsit Digital de la UB
Universidad de Barcelona
European Journal of Cancer
European Journal of Cancer, 2021, 146, pp.30-47. ⟨10.1016/j.ejca.2020.12.023⟩
European Journal of Cancer, Elsevier, 2021, 146, pp.30-47. ⟨10.1016/j.ejca.2020.12.023⟩
Universidad de Barcelona
European Journal of Cancer
European Journal of Cancer, 2021, 146, pp.30-47. ⟨10.1016/j.ejca.2020.12.023⟩
European Journal of Cancer, Elsevier, 2021, 146, pp.30-47. ⟨10.1016/j.ejca.2020.12.023⟩
BRCA1 and BRCA2 gene pathogenic variants account for most hereditary breast cancer and are increasingly used to determine eligibility for PARP inhibitor (PARPi) therapy of BRCA-related cancer. Because issues of BRCA testing in clinical practice now o
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d68784e83fff96e28dfb34c7477a991a
http://hdl.handle.net/2445/176353
http://hdl.handle.net/2445/176353
Autor:
Daniel Zarca, Anne-Paule Gimenez-Roqueplo, Carole Corsini, Dominique Vaur, Nelly Burnichon, Sylviane Olschwang, Christian Hervé, Stéphane Richard, Virginie Galibert, Pascal Pujol, Nadem Soufir, Thierry Frebourg, I. Raingeard, Pierre Vande Perre, Sophie Giraud, Laurence Faivre, Xavier Rebillard, Michèle Anahory, Damien Sanlaville, Olivier Ingster, Muriel Le Bidan, Marc Spielmann, Alain Toledano, Anne Cambon-Thomsen, Brigitte Bressac-de Paillerets, Elisabeth Luporsi, Bernard Baertschi, David Azria, Olivier Cussenot, Pascal Hammel, Noëlle Bastide, Karen Baudry, Isabelle Coupier, Olivier Putois, Arash Rafii, Jean-Philippe Spano, Joseph Gligorov, Sarah Amar, Caroline Zorn, Patricia Niccoli, Michèle Vintraud, Anne-Sophie Lapointe, Olivier Caron, Jean-Marc Rey, David Geneviève, Pierre Le Coz
Publikováno v:
European Journal of Human Genetics
European Journal of Human Genetics, 2018, 26 (12), pp.1732-1742. ⟨10.1038/s41431-018-0224-1⟩
European Journal of Human Genetics, Nature Publishing Group, 2018, 26 (12), pp.1732-1742. ⟨10.1038/s41431-018-0224-1⟩
European Journal of Human Genetics, 2018, 26 (12), pp.1732-1742. ⟨10.1038/s41431-018-0224-1⟩
European Journal of Human Genetics, Nature Publishing Group, 2018, 26 (12), pp.1732-1742. ⟨10.1038/s41431-018-0224-1⟩
IF 3.636 (2017); International audience; In oncology, the expanding use of multi-gene panels to explore familial cancer predisposition and tumor genome analysis has led to increased secondary findings discoveries (SFs) and has given rise to important
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8fe39cbca491f5aa5df412a9e2133e01
https://hal.umontpellier.fr/hal-01870352
https://hal.umontpellier.fr/hal-01870352